Innovative Diagnostics Ties Up with Lucence Diagnostics to Provide Genetic Tests for Personalized Treatment

In Media Releases
June 25, 2018

Innovative Diagnostics, a leading medical diagnostic laboratory in Singapore and Hong Kong, and Lucence Diagnostics, a clinical genetics company focusing on inventing advanced cancer diagnostics, announced today a partnership to provide genetic tests for more personalized and targeted treatment of cancer. The goal of the collaboration is to advance precision medicine in Singapore.

Lucence invents blood tests to detect and track cancer gene mutations for faster and more precise treatment. Requiring only a single draw of blood, the tests can match a specific cancer mutation to a targeted treatment. It can also diagnose early stage cancer before symptoms appear and determine a person’s genetic risk of developing cancer. The tests are based on its patented liquid biopsy technology, which target the most common cancers in Asia including breast, colon and lung cancers.

Innovative Diagnostics provides clinical diagnostics laboratory services and has the widest coverage of any private medical laboratory in Singapore. With this partnership, Lucence’s range of tests will be extended to Innovative Diagnostics’ customer base of general practitioners, specialists, clinics and hospitals in Singapore. The testing service will be supported by Lucence’s ISO15189:2012 accredited molecular diagnostics laboratory.

“Innovative Diagnostics is always looking for new ways to enable doctors to make diagnoses and decisions with confidence. Hence, we are excited to include Lucence’s cutting-edge genetic tests in our panel, which will allow doctors to make more informed treatment decisions based on the genetic profiles of their patients,” said Ms. Ginny Foo, CEO, Innovative Diagnostics.

“We are delighted to partner Innovative Diagnostics to deliver our proprietary genetic tests for targeted treatment and cancer risk assessment to their customers. This partnership will enable more patients in Singapore and the region to benefit from advanced cancer screening and personalized treatment,” said Dr. Min-Han Tan, Founder and CEO, Lucence Diagnostics.

For further information, please contact:

Lucence Diagnostics
Elena Tan
[email protected]
Tel: +65 6592 5102

Innovative Diagnostics
Shirley Lim
[email protected]
Tel: +65 6235 6950

About Lucence Diagnostics

Lucence Diagnostics is a clinical genetics company with the mission of fighting cancer through deep innovation. Headquartered in Singapore with operations and partners in Hong Kong and ASEAN, Lucence invents genetic tests for cancer physicians to select the right treatment for their patients. Lucence’s tests target the most common cancers in the world powered by its patented sequencing technology and in-house clinical analytics. Its key operations are supported by an ISO15189:2012 accredited molecular diagnostics laboratory and a clinical cancer genetics medical center.

For more information, please visit www.lucencedx.com.

About Innovative Diagnostics

Innovative Diagnostics is the only community based medical laboratory led and managed by clinicians and pathologists servicing over 1,000 clients across Singapore comprising of general practitioners (GP), specialists, medical clinics, private hospitals, corporate clients, insurance companies, third party administrators and not for profit groups. Innovative Diagnostics is College of American Pathologists (CAP) accredited since 2013 and became the first medical institution in June 2016 in Singapore to be recognized by the Westgard Sigma Verification Program.

Please visit www.innovativelab.com.sg for more information.

Need Help?